MJardin becomes the latest U.S. cannabis company to go public in Canada through a reverse takeover, nearly 20% of marijuana products in California fail tests for potency and purity, and Alaskans’ preference for high-THC products could bankrupt some growers.
Here’s a closer look at some notable developments in the cannabis industry this week.
When MJardin entered into a reverse takeover (RTO) deal with a publicly traded Canadian company – one that no longer has significant operations – the Denver-based firm joined several other private marijuana businesses that have taken that route.
However, any U.S. cannabis company mulling a reverse takeover should do so carefully, according to one industry executive.
RTOs, also known as reverse mergers in the United States, can be a quicker, less involved method of going public.
And Brett Roper, CEO of Denver consultancy Medicine Man Technologies, agreed RTOs can be a good route for a marijuana business to go public. But, he added: “Be careful.”
“They can be risky if (companies haven’t) done their due diligence,” Roper said.
Roper recommends three things to keep in mind when entering into a reverse takeover:
- If you’re going to buy a shell company to complete a reverse takeover, purchase a business that has gone through bankruptcy so all the shares are properly discharged and the new, incoming shareholder group is properly set.
- If you’re making the deal in the United States, be sure your shareholders understand they could be sidelined for a year. Under federal securities law, the shares often are not tradable for one year after the RTO.
- Get professional help in vetting the company you’re looking to purchase. If you’re going public in Canada, hire a Canadian attorney and accountant to help you. “They can go back and sniff the books and look at the ledgers,” Roper said. If they’ve done their job, there shouldn’t be a problem, he added.
There’s no straightforward explanation for the rash of cannabis product testing failures in California over the past few months. Similarly, there’s no simple answer.
Moreover, the high failure rate – close to 20% – is unlikely to let up anytime soon.
That’s according to two industry experts in the Golden State: MMLG Consulting’s compliance director, Dr. Juli Crockett, and K Street Consulting’s legislative advocate, Max Mikalonis.
Both agreed the majority of testing failures – 67% resulted from inaccurate labels on cannabis products versus pesticide contamination or microbial impurities – were more likely the result of overly stringent regulations than anything else.
“The sequence that operators are required to follow makes it that you have to label the product before you get it tested, and that’s setting everyone up to fail,” Crockett said.
Manufacturers often use one lab to get an idea of their product’s chemical content and print out a label for the product line, and then the distributor may use a yet another lab, which can lead to different results and an official failure.
On top of that, the allowable 10% variance in testing results compared to what’s on a product label creates a “very slim” window for error, Crockett said – especially with microdose products that may have just a few milligrams of THC or even less than a milligram of CBD, for instance.
That makes it incredibly difficult for labs and manufacturers to hit the correct target, Crockett said.
“Then it gets interpreted as: ‘All these irresponsible people are putting poison on the market,'” Crockett said, which she added is far from the truth.
Mikalonis noted that most cannabis products already face more stringent safety testing than many foods that are considered safe for consumption.
“Our cannabis is cleaner than our food and our water,” Mikalonis said.
Alaska THC potency fallout
“Literally, companies are going bankrupt,” said Leif Abel, co-owner of Greatland Ganja and vice president of the Alaska Marijuana Industry Association.
He said Greatland had to lay off two employees last winter when it was forced to reduce prices 40% because of Alaskans’ preference for high-THC products.
“It’s almost like a vicious cycle,” said Leah Levinton, co-owner of Enlighten Alaska, a retail shop in Anchorage. “It’s what consumers want, so retailers are basing their pricing structure on THC, then pushing the cultivator to sell lower THC (products) at a lower price.”
Abel and Levinton attributed the obsession over THC potency to the relative youth of Alaska’s rec MJ market, although culture could also play a role, Levinton said. The state’s recreational marijuana market launched in late 2016.
Alaskans have a “hard-core, rugged mentality that we’ll do everything to the extreme, whether it’s river rafting or smoking weed very hard,” Levinton said.
Levinton and Abel suggested the following to break the cycle:
- Educate consumers about the benefits of lower THC products – i.e., “You won’t find yourself curled up in a hallucinatory state.”
- Train budtenders to highlight a variety of products.
- Growers and processors should promote strains and creative packaging.
Bart Schaneman can be reached at [email protected]
John Schroyer can be reached at [email protected]
Jeff Smith can be reached at [email protected]